| 臺大學術典藏 |
2022-02-18T06:28:52Z |
Higher risk of advanced histology in adenoma less than 10 mm in fecal immunochemical test screening: Implication for management
|
WEN-FENG HSU; Cheng S.-Y.; Shun C.-T.; Chang L.-C.; Tu C.-H.; Wang H.-P.; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-18T06:28:51Z |
Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program
|
WEN-FENG HSU; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-18T06:28:50Z |
Recurrence Outcomes Less Favorable in T1 Rectal Cancer than in T1 Colon Cancer
|
Chang L.-C.; Shun C.-T.; Lin B.-R.; Sanduleanu S.; WEN-FENG HSU; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-18T06:28:50Z |
Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme
|
Peng S.-M.; WEN-FENG HSU; Wang Y.-W.; Lin L.-J.; Yen A.M.-F.; Chen L.-S.; Lee Y.-C.; Wu M.-S.; Chen T.H.-H.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-18T06:28:50Z |
Impact of COVID-19 pandemic on fecal immunochemical test screening uptake and compliance to diagnostic colonoscopy
|
Cheng S.-Y.; Chen C.-F.; He H.-C.; Chang L.-C.; WEN-FENG HSU; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-18T06:28:49Z |
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers
|
Chiu H.-M.; Jen G.H.-H.; Wang Y.-W.; Fann J.C.-Y.; Hsu C.-Y.; Jeng Y.-C.; Yen A.M.-F.; Chiu S.Y.-H.; Chen S.L.-S.; WEN-FENG HSU; Lee Y.-C.; Wu M.-S.; Wu C.-Y.; Jou Y.-Y.; Chen T.H.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:55Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chang C.-Y.; YU-JEN FANG; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:54Z |
Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
|
Han M.-L.; Lee Y.-C.; Chen C.-C.; YU-JEN FANG; Lee J.-Y.; Lin T.-L.; Lin L.-W.; Tseng P.-H.; Wu M.-S.; Wang H.-P. |
| 臺大學術典藏 |
2022-02-14T06:28:53Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; YU-JEN FANG; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:53Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; YU-JEN FANG; Hsu S.-J.; Han M.-L.; Tseng P.-H.; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:52Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; YU-JEN FANG; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:52Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; YU-JEN FANG; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2022-02-14T06:28:51Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
YU-JEN FANG; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:51Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; YU-JEN FANG; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:50Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; YU-JEN FANG; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:50Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; YU-JEN FANG; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:49Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; YU-JEN FANG; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chen C.-C.; Chen C.-C.; YU-JEN FANG; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; Chen Y.-N.; Chen C.-C.; YU-JEN FANG; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; YU-JEN FANG; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; YU-JEN FANG; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:46Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; YU-JEN FANG; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:44Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; YU-JEN FANG; Wu M.-S.; Chen C.-C.; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:44Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
YU-JEN FANG; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; Wu M.-S.; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2022-02-14T06:28:43Z |
Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles
|
Chen C.-C.; Wu W.-K.; Chang C.-M.; Panyod S.; Lu T.-P.; Liou J.-M.; YU-JEN FANG; Chuang E.Y.; Wu M.-S. |
